Literature DB >> 2116773

Does steroid pulsing influence the efficacy and toxicity of chrysotherapy? A double blind, placebo controlled study.

C S Wong1, G Champion, M D Smith, M Soden, M Wetherall, R A Geddes, W R Hill, M J Ahern, P J Roberts-Thomson.   

Abstract

To test the hypothesis that early steroid pulsing augments the efficacy and decreases the toxicity of chrysotherapy 40 patients with rheumatoid arthritis were studied in a double blind, placebo controlled study. During the first three months of gold treatment group 1 received monthly intravenous methylprednisolone pulsing (steroid group) while group 2 received placebo (placebo group). All patients were assessed clinically and serologically over a 24 week period. Twelve patients were withdrawn before completion of the study and all but one of the remaining 28 patients reported clinical and serological improvements. Two patients in the steroid group were withdrawn owing to gold induced side effects while four were withdrawn in the placebo group. These small numbers were not significantly different. Minor side effects occurred more commonly in the placebo group. The clinical response was clearly better in the steroid group with statistical significance almost being achieved. In an endeavour to obtain a significant conclusion further patients will now be entered into this study.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2116773      PMCID: PMC1004102          DOI: 10.1136/ard.49.6.370

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. I. Clinical effects.

Authors:  M D Smith; J V Bertouch; A M Smith; M Weatherall; M J Ahern; P M Brooks; P J Roberts-Thomson
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

2.  Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone?

Authors:  M D Smith; M J Ahern; P J Roberts-Thomson
Journal:  Ann Rheum Dis       Date:  1988-01       Impact factor: 19.103

3.  Pulse methylprednisolone in rheumatoid arthritis: a double-blind cross-over trial.

Authors:  M R Liebling; E Leib; K McLaughlin; K Blocka; D E Furst; K Nyman; H E Paulus
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391

4.  Combination therapy with pulsed methylprednisolone in rheumatoid arthritis.

Authors:  V Neumann; R Hopkins; J Dixon; A Watkins; H Bird; V Wright
Journal:  Ann Rheum Dis       Date:  1985-11       Impact factor: 19.103

5.  A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease.

Authors:  I A Williams; E M Baylis; M E Shipley
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

6.  Combined suppressive drug treatment in severe refractory rheumatoid disease: an analysis of the relative effects of parenteral methylprednisolone, cyclophosphamide, and sodium aurothiomalate.

Authors:  M T Walters; M I Cawley
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

  6 in total
  4 in total

1.  Fatal acute pyelonephritis following pulsed methylprednisolone for rheumatoid arthritis.

Authors:  D A Walsh; R A Durance
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

2.  Pulsed methylprednisolone for rheumatoid arthritis.

Authors:  M D Smith
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

3.  A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs.

Authors:  E H Choy; G H Kingsley; B Khoshaba; N Pipitone; D L Scott
Journal:  Ann Rheum Dis       Date:  2005-03-10       Impact factor: 19.103

Review 4.  The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses.

Authors:  William G Dixon; Samy Suissa; Marie Hudson
Journal:  Arthritis Res Ther       Date:  2011-08-31       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.